Aurora Spine ($ASG) Engineering the Re-Rating
Prio Brief #7 | Piecing together the mosaic behind a major structural shift built for pure commercial speed
We are releasing a relevant update on Aurora Spine Corporation ($ASG).
Note that this is a material change and the information has been vetted by 3 independent sources.
As always, we’ve included our usual short overview of Aurora Spine to start, but if you already know the company, feel free to skip straight to the major update.
Priority Briefings. Investing is dynamic, so our research never sits still. We don’t file a report and walk away; we maintain an active, ongoing dialogue with the key stakeholders and management teams of our past, present and future holdings.
Think of these briefs as your “insider access” to those calls. We strip away the corporate speak to bring you the direct highlights and actionable updates. You’ll see exactly how the business is evolving in real-time, long before it hits the quarterly report.
This series is exclusively for 🧙♂️ Inner Circle members
None of the following should be construed as investment advice. Please consult a financial advisor before making any investment decision. You will find a full disclaimer at the end of this post.
Aurora Spine Corporation ($ASG) Brief
Aurora Spine is a medical technology disruptor turning the massive $10bn spinal implant market on its head. While they are technically a Canadian-listed entity (trading on the TSXV), they hang their hats in Carlsbad, California, operating as one of the few hardware designers of minimally invasive surgery devices.
Unlike the old-school one-size-fits-all metal hardware that treats every spine the same, Aurora has developed smart (regenerative) implants that mimic a patient’s actual anatomy.
They are precision engineers of the human back looking to fill in the void for interventionalists and surgeons combined.
Product Overview
Aurora focuses on high-tech platforms designed to make surgeries faster, safer, and way less painful:
DEXA Platforms: Traditional spinal implants are often too stiff, causing them to sink into the bone over time. Aurora’s DEXA implants are 3D-printed to match a patient’s specific bone density. They just secured their 4th US Patent for this tech in May 2026, and they are launching the expanded DEXA-L (for the lumbar spine) in Q3 2026!
SiLO & SiLO-TFX: These systems target Sacroiliac (SI) joint pain. Instead of massive, muscle-tearing surgeries, doctors use a tiny incision to stabilize the joint, resulting in lightning-fast recovery times.
Zip & Aurora Biologics: Launched in late 2025, their new biologics division is already a rockstar, posting a 124% sales bump in Q1 2026. They now pair these regenerative biologics with their implants for better bone healing.
Recent Financials
Aurora spent over a decade building its IP fortress, and the business has officially shifted into commercialization, making the company self-sustaining since 2025:
(Juicy) 62.6% Margins: By aggressively swapping out third-party products for their own proprietary hardware, gross profit margins climbed to an impressive 62.6% in early 2026.
Free Cash Flow (FCF) Nearing Breakeven: For Q1 2026, operational cash burn slowed to a crawl at just -$13k. When you drop in their capital expenditures ($22k for equipment and tech additions), their Q1 FCF sat at -$35k. Compare that to the painful -$320k FCF burn in Q1 2025, and it's clear they are right on the cusp of self-sustainability (especially considering they pulled in a sweet total $373k in positive FCF for FY2025).
Cash Management: In March 2026, the company pulled off a savvy financial move by renegotiating an insider loan, slashing the interest rate in half (from 9% to 4.5%) and pushing the due date out to 2029 to keep cash in the bank.
Ready for the full backbone of the story? Catch our complete long-form dive into Aurora's 2026 outlook right here:
Now onto the…